LETTER TO THE EDITOR

Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes

Authors

Agata Gruszczynska,[1] Abhishek Maiti,[2] Christopher A. Miller,[1] Sai Mukund Ramakrishnan,[1] Daniel C. Link,[1] Geoffrey L. Uy,[1] Allegra A. Petti,[3] Kala Hayes,[2] Courtney D. DiNardo,[2] Farhad Ravandi,[2] Timothy J. Ley,[1] David H. Spencer,[4] Feng Gao,[5] Marina Y. Konopleva[6] and John S. Welch[1°]

[1]Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MI; [2]Department of Leukemia, MD Anderson Cancer Center, Houston, TX; [3]Department of Neurosurgery, Washington University School of Medicine, St. Louis, MI; [4]Department of Pathology, Washington University School of Medicine, St. Louis, MO; [5]Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MI and [6]Albert Einstein College of Medicine, Bronx, NY , USA

°Current address: A2 Biotherapeutics, Agoura Hills, CA, USA

Correspondence:
J.S. WELCH - jwelch@a2biotherapeutics.com

https://doi.org/10.3324/haematol.2022.281396



Supplemental Figure 1







Supplemental Figure2



Supplemental Figure3



Supplemental Figure 4

Supplemental Figure 1. Representative calculations of molecular responses. A-F. Single-agent decitabine cases with stable disease. D-F. Single-agent decitabine cases with stable disease during the first 1-2 cycles followed by molecular response. G-I. Decitabine/venetoclax cases. Note responses after the first cycle.

Supplemental Figure 2. Molecular subgroup analysis. A-C. Comparison of tumor burden and molecular responses measured in BM and PB substrates from patients with MDS and sAML. D-E. Comparison of molecular responses within morphologic responses. One-way ANOVA with Dunn's multiple comparison. F-G. Comparison of molecular responses within de novo AML patients comparing CR vs. other responders (e.g. CRi/mLFS). One-way ANOVA with Dunn's multiple comparison.

Supplemental Figure 3. Clinical subgroup analysis. A-F. Impact of clinical features on overall survival within the total cohort of patients (n=95). G-H. Impact of adverse risk karyotypes within treatment cohorts. Log-rank comparisons.

Supplemental Figure 4. Subgroup analysis of overall survival based on treatment and the presence of specific gene mutations.